REGN241220P820000
- 90.40
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating
Regeneron Reports Positive Results for Two Anti-coagulant Drugs
Express News | Regeneron Pharmaceuticals Inc - Regn7508 and Regn9933 Evaluated for Thrombosis Control
Express News | Regeneron Pharmaceuticals Inc - Phase 3 Program to Begin in 2025
Regeneron to Advance Two Factor XI Antibodies Into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
Leerink Partners Keeps Their Hold Rating on Regeneron (REGN)
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Express News | Regeneron Pharmaceuticals Shares Are Trading Higher After the Company Announced Its QUASAR Trial Investigating EYLEA HD Met Its Primary Endpoint for the Treatment of Patients With Macular Edema
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock